Immunotoxins in the therapy of cancer

From bench to clinic

Victor Ghetie, Ellen Vitetta

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.

Original languageEnglish (US)
Pages (from-to)209-234
Number of pages26
JournalPharmacology and Therapeutics
Volume63
Issue number3
DOIs
StatePublished - 1994

Fingerprint

Ribosome Inactivating Proteins
Immunotoxins
Monoclonal Antibodies
Clinical Trials
Neoplasms
Therapeutics

Keywords

  • cancer
  • Immunotoxin
  • monoclonal antibody
  • therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Immunotoxins in the therapy of cancer : From bench to clinic. / Ghetie, Victor; Vitetta, Ellen.

In: Pharmacology and Therapeutics, Vol. 63, No. 3, 1994, p. 209-234.

Research output: Contribution to journalArticle

@article{f4de2f507e9840eabdb56098d177ee7d,
title = "Immunotoxins in the therapy of cancer: From bench to clinic",
abstract = "This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.",
keywords = "cancer, Immunotoxin, monoclonal antibody, therapy",
author = "Victor Ghetie and Ellen Vitetta",
year = "1994",
doi = "10.1016/0163-7258(94)90025-6",
language = "English (US)",
volume = "63",
pages = "209--234",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Immunotoxins in the therapy of cancer

T2 - From bench to clinic

AU - Ghetie, Victor

AU - Vitetta, Ellen

PY - 1994

Y1 - 1994

N2 - This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.

AB - This review presents only those contributions that have progressed from the bench to the clinic using murine monoclonal antibodies coupled chemically to toxins, their subunits or ribosome-inactivating proteins. The rationale and progress in the development, characterization, preclinical testing and clinical trials are discussed.

KW - cancer

KW - Immunotoxin

KW - monoclonal antibody

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=0028062734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028062734&partnerID=8YFLogxK

U2 - 10.1016/0163-7258(94)90025-6

DO - 10.1016/0163-7258(94)90025-6

M3 - Article

VL - 63

SP - 209

EP - 234

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -